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Abstract
Background: The use of vancomycin has continued to expand because of the increasing number of patients in-
fected or colonized with methicillin-resistant Staphylococcus aureus, causing an increase in the prevalence of van-
comycin-resistant Enterococcus (VRE).
Methods: Review of the pertinent English language literature.
Results: Vancomycin-resistant Enterococcus spp. are being identified more often in nosocomial infections of sur-
gical patients. The biology of resistance, modes of transmission, patient risk factors, and current treatment strate-
gies are discussed.
Conclusions: The reservoir of resistance in enterococci looms as a major threat for genetic transfer and the emer-
gence of increasing numbers of vancomycin-resistant S. aureus.
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VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) is an in-creasing problem worldwide. Approximately 30% of en-
terococci isolated from patients in intensive care units (ICUs)
in the United States carry this resistance trait [1]. Bacteremia
and endocarditis caused by these organisms are being re-
ported with increasing frequency, and these organisms also
can be involved in urinary tract, intra-abdominal, and skin
and soft tissue infections. However, of potentially greater im-
portance, the transfer of vancomycin resistance to other gram-
positive organisms, particularly staphylococci, remains a
threat. In this paper, the epidemiology and risk factors for
colonization with VRE are reviewed, as are measures to pre-
vent the spread of VRE colonization. In addition, antibiotic
therapy for infections attributable to VRE is discussed.
Overview
Enterococcus spp. are part of the normal human intestinal
flora. Enterococcus faecalis and E. faecium account for most hu-
man infections with enterococci. Enterococcus faecalis infec-
tions tend to be observed in patients who have not had ex-
tensive exposure to antibiotics, whereas E. faecium infections
are more common in patients heavily treated with antibiot-
ics, particularly in an ICU setting.
Enterococcus infections are inherently difficult to treat be-
cause of both intrinsic and acquired resistance to many an-
tibiotics. These organisms are intrinsically resistant to tri-
methoprim-sulfamethoxazole, many penicillins other than
selected aminopenicillins and ureidopenicillins, and all ceph-
alosporins with the possible exception of ceftobiprole and
ceftaroline, currently undergoing clinical evaluation. In ad-
dition, enterococci have acquired resistance to many other
classes of antibiotics, to which the organisms are not in-
trinsically resistant, including tetracyclines, macrolides, lin-
cosamines, fluoroquinolones, aminoglycosides, and peni-
cillins. Many strains of E. faecalis are susceptible to certain
penicillins, carbapenems, and fluoroquinolones; however,
virtually all strains of E. faecium are resistant to these 
agents [2].
Resistance of enterococci to vancomycin was first reported
in Europe in 1986; the first case report in the United States
followed the next year. Since that time, VRE has been iden-
tified worldwide. Although fewer than 10% of E. faecalis iso-
lates from ICU patients with enterococcal infections are
vancomycin-resistant, 70% of the E. faecium isolates are re-
sistant [3].
Resistance is attributable to a series of transposable genetic
elements collectively termed the van gene complexes. These
elements also confer resistance to teicoplanin and, to vari-
able degrees, other glycopeptides. They alter the binding tar-
get for vancomycin in the synthesis of bacterial cell wall pre-
cursors. Six van gene complexes have been described, of
which vanA and vanB are the most relevant clinically. The
vanA gene complex confers high-level resistance to vanco-
mycin and teicoplanin, whereas vanB confers moderate to
high-level resistance to vancomycin only [2].
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The potential transmission of vancomycin resistance to
staphylococci is of great concern. It has been estimated that
9.5%–19% of patients colonized with VRE also are colonized
with methicillin-resistant Staphylococcus aureus (MRSA)
[4–6]. Specifically, one study of ICU patients at two acade-
mic medical centers identified 3% of patients as being co-col-
onized, with 40% of those being colonized at the same
perirectal site [5]. Thus, opportunities for transmission of ge-
netic information seem relatively common. There have been
reports of such transmission, the first case being reported in
2003 [7]. The frequency of this transmission, and the capac-
ity of these staphylococci to colonize and spread to other in-
dividuals, is not known. However, widespread emergence
of staphylococci with high-level resistance to vancomycin
and other glycopeptides would have a major impact on man-
agement of infections attributable to these organisms.
Acquisition of VRE
The primary reservoirs from which patients acquire VRE
are other patients already colonized with the organisms. In
addition, the healthcare environment, where the organism
can survive as long as 7 days, probably plays a reservoir role
as well. In some European countries, animal reservoirs have
proved to be a source of VRE transmission to individuals
outside the healthcare setting. The use of avoparcin, a gly-
copeptide antibiotic, as a growth promoter in animal hus-
bandry was implicated in the maintenance of VRE in these
animal sources [8].
Colonization with VRE appears to require not only expo-
sure to the organism but also the presence of a susceptible
host [8,9] (Table 1). The patients most likely to be colonized
are elderly, severely ill individuals with multiple co-mor-
bidities. These patients tend to be housed for long periods
of time in areas of the hospital, such as ICUs, where VRE en-
demicity is highest.
An additional risk factor for VRE acquisition is exposure
to antibiotics. Several agents have been implicated, but use
of vancomycin and third-generation cephalosporins appears
to be associated most commonly with the spread of this or-
ganism. Two studies suggested that altering antibiotic choice
may influence the spread of VRE. In these studies, lower
rates of VRE colonization were identified after the substitu-
tion of piperacillin/tazobactam, an antibiotic with anti-ente-
rococcal activity, for ceftazidime or ticarcillin/clavulanic
acid, antibiotics that lack such activity [10,11].
Although the emphasis on recognizing hosts susceptible
to VRE is of some importance, one cannot overlook the fact
that these patients have to acquire VRE from a source [8].
Thus, the proximity and duration of exposure to patients or
environmental reservoirs of VRE probably is the most im-
portant risk factor for acquisition of VRE. This was clearly
demonstrated by Byers et al., who identified proximity to an
unisolated VRE case as a highly significant risk factor for col-
onization with VRE, outweighing all other risk factors [12].
Thus, high rates of colonization within an institutional set-
ting lead to perpetuation of the epidemic.
Vancomycin-resistant enterococci can be transmitted read-
ily between patients on the hands of healthcare workers. One
study showed that VRE could be recovered from the hands
of 13–43% of workers who were caring for colonized patients
[13]. Thus, healthcare workers may help perpetuate an epi-
demic once VRE has gained a foothold within the institu-
tion.
VRE Surveillance
In order to prevent further spread of VRE, rigorous infec-
tion control measures must be employed. Active surveillance
and isolation are the primary tools. Active surveillance,
which involves screening of asymptomatic patients at risk
for carrying the organism, is necessary because only a small
fraction of the patients colonized with VRE are identified
from positive cultures. The efficacy of this approach has been
demonstrated in The Netherlands, where a nationwide pro-
gram of active surveillance and isolation has led to very low
rates of VRE acquisition; fewer than 2% of enterococcal iso-
lates in The Netherlands are resistant to vancomycin [3].
There are many issues to be considered in screening.
Screening of all patients likely would be cost prohibitive, but
selected screening of patients admitted to wards where the
prevalence of VRE is greater than 20% has been proposed
[8]. Other issues include the frequency with which screen-
ing should be undertaken, the patient site(s) to be utilized,
and the specific laboratory method used. For instance, stool
cultures are considered the gold standard for detecting VRE,
but most screening involves rectal or perirectal sampling.
Detection at that site is a function of the concentration of VRE
in the stool, as well as the current exposure of the patient to
antibiotics, potentially decreasing the sensitivity of detection
[14,15].
Once a patient is identified as being colonized with VRE,
contact isolation procedures should be initiated. An unre-
solved question is how long such patients need to remain
isolated. Many of the chronically ill patients colonized with
VRE can be expected to be rehospitalized. Unfortunately,
VRE carriage appears to be prolonged, if not permanent. In
one study, 43% of pediatric oncology patients colonized with
VRE remained persistent carriers, with VRE being excreted
for a median of 112 days [16]. In another study, 61% of adult
oncology patients were still colonized with VRE on re-ad-
mission to the hospital, with the sicker patients more likely
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to remain colonized [17]. Thus, there is no specific answer
as to when patients colonized with VRE can be removed
from isolation. The current recommendation from the U.S.
Centers for Disease Control and Prevention (CDC) are that
“stringent criteria might be appropriate, such as VRE-nega-
tive results on at least three consecutive occasions ( 1 week
apart) for all cultures from multiple body sites . . . “
Nonetheless, active surveillance and isolation for VRE re-
main controversial [19]. Proponents note the success of in-
fection control programs in the control of disease processes
such as tuberculosis, smallpox, and, more recently, severe
acute respiratory syndrome (SARS). They also point to the
potential risk that dissemination of VRE will lead inevitably
to wider development of glycopeptide-resistant staphylo-
cocci. However, opponents question the value of these pro-
grams, noting that infections caused by VRE are relatively
uncommon, and tend to occur in patients who typically will
acquire infections with resistant pathogens in any case. Some
also believe that colonization is already too widespread in
the healthcare environment, and that infection control efforts
may result only in the near-universal isolation of all hospi-
talized patients, which may be deleterious to care as a result
of decreased patient contact with healthcare providers. Fi-
nally, despite numerous opportunities for transmission of
vanA to staphylococci, vancomycin-resistant staphylococci
continue to be rare. Thus, at present, there is no consensus
on whether active surveillance and isolation for VRE is a
worthwhile pursuit.
Infections Caused by VRE
Infections develop in patients who have already been col-
onized with VRE [9]. The types of infections are similar to
those seen with typical enterococci, with intra-abdominal,
skin and soft tissue, urinary tract, and blood stream infec-
tion and endocarditis being the most common. Three per-
cent of patients with VRE bacteremia reportedly develop en-
docarditis [20]. Vancomycin-resistant enterococcal infections
of the central nervous system are uncommon, and respira-
tory infections are rare.
Vancomycin-resistant enterococcal infections are most
common in immunocompromised patients [9]. The patients
at highest risk are those with hematologic malignant tumors,
particular those treated with bone marrow transplants. Pa-
tients with solid organ allografts also represent a group at
higher risk for VRE infections. Patients with liver transplants
may develop VRE infections related to the biliary tract, prob-
ably because of the innate capacity of enterococci to survive
in an environment where there are high concentrations of
bile salts.
The implication of an infection by VRE remains uncertain.
A meta-analysis of 13 studies of patients with vancomycin-
resistant vs. vancomycin-sensitive enterococcal bacteremias
suggested a higher risk of death related to infection by VRE
(RR  2.57; 95% confidence interval [CI], 2.27–2.91). The
mortality rate attributable to infection with the vancomycin-
resistant strain was estimated at 17%. The hospital stay was
2.9 to 27 days longer in patients with infections caused by
VRE [21]. Another study focused on patients with liver
allografts who developed infections with VRE. In these 19
patients, VRE was cultured from the blood in 35% of pa-
tients, the peritoneal fluid in 20%, bile in 20%, and urine in
14%. The survival of patients with VRE infections was 52%,
compared with 82% in matched patients without this infec-
tion [22].
Nonetheless, some authorities believe that the high mor-
tality rates observed in patients with VRE infections reflect
their complicated medical conditions, and are not attribut-
able specifically to VRE. They point out to the inherent dif-
ficulty of attributing death in these patients to a VRE infec-
tion when there are so many other medical co-morbidities.
Further, they point out that many of the studies showing
high mortality rates from VRE infections took place before
more effective therapy for VRE was available [23,24].
Antibiotics for VRE Infections
A number of agents are potentially useful in the treatment
of infections caused by VRE (Table 2). Certain older agents
can be used. Some aminopenicillins and ureidopenicillins
(such as ampicillin and piperacillin) have activity against the
occasional strain of vancomycin-resistant E. faecalis [9,25].
However, virtually all strains of E. faecium are resistant, so
these agents are not useful for the majority of VRE infections.
Older tetracyclines, such as doxycycline and minocycline,
have been used. However, a report on urinary isolates of
vancomycin-resistant E. faecium indicated that only 60% of
strains were fully sensitive to doxycycline [26]. In addition,
many authorities would question the use of these agents for
VRE bacteremia, as they are considered bacteriostatic rather
than bactericidal.
Chloramphenicol has been successful for the treatment of
VRE infections. In the survey of urinary isolates of vanco-
mycin-resistant E. faecium, nearly all strains were susceptible
to this drug [26]. However, additional reports now indicate
emergence of strains of VRE resistant to chloramphenicol,
particularly as its use has increased [27].
Among newer agents, quinupristin/dalfopristin has been
useful in the treatment of infections caused by VRE. Of note,
this agent is useful only for E. faecium infections, because E.
faecalis has intrinsic resistance [9,25]. Clinical response rates
of 71–83% have been reported when this agent has been used
to treat patients with VRE infections. However, quin-
upristin/dalfopristin has been reported to be associated with
relatively high rates of side effects, especially arthralgias
(33% of treated patients) and myalgias (47% of treated pa-
tients). In addition, this antibiotic generally must be admin-
istered through a central venous catheter [25,28] because of
the high incidence of phlebitis. Resistance to quinupristin/
dalfopristin has been reported in 1.3–2.4% of patients with
vancomycin-resistant E. faecium [26,29].
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TABLE 2. ANTIBIOTICS FOR TREATMENT OF INFECTIONS
CAUSED BY VANCOMYCIN-RESISTANT ENTEROCOCCI
Selected aminopenicillins, ureidopenicillins, and 
carbapenems (E. faecalis strains only)
Doxycycline, minocycline
Chloramphenicol




Linezolid probably is the agent used most often for the
treatment of VRE infections with the exception of bacteremia.
Clinical response rates of 67–81% have been reported [25,28].
In solid organ allograft recipients, mortality rates of 33% for
all patients and 42% for liver transplant patients were re-
ported when linezolid was used to treat VRE infections.
These rates were substantially decreased relative to the
53–83% rates in historical controls [30]. A randomized con-
trolled trial in 40 cancer patients with vancomycin-resistant
E. faecium infections compared linezolid with quinupristin/
dalfopristin; the clinical response rates were 58% for line-
zolid and 43% quinupristin/dalfopristin [31]. Nonetheless,
resistance of VRE to linezolid has surfaced, as with most
other antibiotics. In a report from the M.D. Anderson Can-
cer Center, susceptibility of vancomycin-resistant E. faecium
to linezolid decreased to 83% six months after inclusion of
linezolid on the hospital formulary [32]. Although linezolid
generally has been safe, development of thrombocytopenia
or other evidence of bone marrow suppression may be an
important limiting side effect, particularly in immunosup-
pressed or cancer patients [29].
Daptomycin also has good in vitro activity against VRE.
This agent is bactericidal rapidly, and theoretically might be
preferred for patients with VRE bacteremia or endocarditis
[29]. However, experience in the treatment of VRE is rela-
tively limited. In one series of eleven patients with VRE bac-
teremia, treatment success was noted in five [33]. In another
series of neutropenic patients with bacteremia, four of nine
patients were treated successfully [34]. As with other antibi-
otics, resistance of VRE to daptomycin has emerged [9,29].
Tigecycline, a recently released glycylcycline, has good in
vitro activity against VRE. However, there are few published
data regarding treatment of VRE infections with this agent.
Because it is bacteriostatic and achieves relatively low serum
concentrations, it may not be ideal for patients with bac-
teremia. Its utility in patients with VRE resistant to older
tetracyclines such as minocycline has yet to be determined
[9,28,29].
Conclusions
Colonization of hospitalized patients with VRE has be-
come common throughout the world. Colonization is most
common in the critically ill patient, whose concurrent illness
and exposure to antimicrobial therapy facilitates acquisition
of resistant organisms, and who is housed in a healthcare
setting where exposure to previously colonized individuals
and environmental sources is facilitated. Active surveillance
for VRE and isolation of colonized patients may decrease the
spread of this organism. The typical patient who develops
an overt infection attributable to VRE is immunosuppressed
and has been colonized previously with the organism. Al-
though several antibiotics have activity against VRE, the
mortality rate in patients with infections caused by VRE re-
mains high.
The development of larger numbers of infections caused
by VRE is a major clinical problem, particularly for the crit-
ically ill or immunosuppressed patient. However, dissem-
ination of this resistant organism is of further concern be-
cause of the potential for transfer of the vancomycin
resistance genetic trait to S. aureus. This event has been doc-
umented clinically, and the frequent co-colonization of pa-
tients with both MRSA and VRE suggests that such trans-
fer may occur with increasing frequency in the future. This
prospect of widespread development of vancomycin-resis-
tant S. aureus also argues for continued diligence in efforts
to control VRE.
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